Exonate is developing eye drops to revolutionise the current standard-of-care in the treatment of eye diseases.
Exonate, an early stage biotechnology company, today announces the launch of its newly developed website. The website has been created by the team at Onespacemedia, an award winning digital agency based in the heart of Cambridge.
Onespacemedia were commissioned by Exonate to develop a strong, contemporary and sector appropriate
web presence and to elevate the Company’s profile using leading design techniques. Exonate wanted to enhance visibility of its science, demonstrate momentum and increase business development and partnership enquiries online. The new website portrays the need for and Exonate’s commitment to developing a revolutionary, game changing eye drop for the treatment of retinal vascular diseases, including wet Age-related Macular degeneration (wAMD) and Diabetic Macular Oedema (DME), by using mRNA targeted therapies.
Commenting on the website Exonate’s CEO Dr Catherine Beech, said: “Working with Onespacemedia has been a really positive experience. They have taken time to truly understand the science behind our Company and designed a modern, expansive and first-class website that emphasises Exonate’s corporate branding and supports our mission to profoundly improve the lives of those suffering from vision loss.”
George Hadfield, Onespacemedia’s Head of Production, commented: “It’s extremely inspiring to be working with the Exonate team whose mission is to change the lives of those suffering from vision loss and retinal vascular diseases. The new site uses leading design and development techniques, which mirrors their own innovation and ambition and gives them a solid digital platform that will support their business objectives going forward.”
For further information please go to our new website: www.exonate.com
Tel: +44 (0) 1223 437042
Louise Shave, Marketing
Tel: +44 (0) 20 3727 1000
Mo Noonan / Lucy McKeone
Exonate is a privately held, early stage, biotech company spun out of the University of Nottingham that is focused on Vascular Endothelial Growth Factor (VEGF) in areas of unmet need, such as ophthalmology, pain, nephropathy and cancer. Exonate’s lead programme is focused on Diabetic macular oedema (DME). A consequence of diabetic retinopathy, DME is swelling in an area of the retina called the macula and wet Age-Related Macular Degeneration (wAMD), which is the leading cause of vision loss in people aged 60 and older. The Company is founded on scientific excellence with strong links to Professor David Bates and his lab at Nottingham University specialising in the biology and biochemical pathways of VEGF splice variants.
Exonate have developed small molecules that inhibit production of pro-angiogenic VEGF through selective inhibition of serine/threonine-protein kinase 1 (SRPK1)-mediated VEGF splicing. These inhibitors have already demonstrated superior efficacy as topical agents in preclinical models of wet AMD. Through a Wellcome Trust funded project, Exonate will complete an optimisation programme to nominate a pre-clinical candidate drug with optimal characteristics ahead of regulatory toxicology and safety pharmacology studies which will support an application to the regulatory authorities for clinical evaluation. Exonate expects to reach this milestone and enter the clinic in early 2020.
Exonate is led by an experienced, international management team that has previously worked together with cross-disciplinary experience in medicine and drug development, as well as successful fundraising for early stage companies.
About Diabetic macular oedema (DME)*
DME is the build-up of fluid (oedema) in a region of the retina called the macula. The macula is important for the sharp, straight-ahead vision that is used for reading, recognising faces, and driving. DME is the most common cause of vision loss among people with diabetic retinopathy. About half of all people with diabetic retinopathy will develop DME and although it is more likely to occur as diabetic retinopathy worsens, DME can happen at any stage of the disease.
About wet Age-Related Macular Degeneration (wAMD)
Today, wAMD is a leading cause of vision loss in people aged 60 years or older and affects more than 30 million patients worldwide, over 200,000 of those in the UK alone. If untreated patients are likely to lose sight in the affected eye within 24 months of disease onset.
The current standard-of-care treatment options for DME and wAMD are
Anti-VEGF antibody drugs – to prevent the growth of new blood vessels in the Unlike small molecule drugs or eye drops, these treatments must be injected into the eye once every 1-2 months. Resistance can develop to these drugs causing the disease to progress anew.
Laser surgery – to destroy abnormal blood vessels in the eye. This type of surgery is only suitable if blood vessel damage is not too extensive and if the abnormal blood vessels aren’t close to the fovea, as performing surgery close to this part of the eye can cause permanent vision.
With DME, Corticosteroids either injected or implanted into the eye, may be used alone or in combination with other drugs or laser surgery to treat DME